1. Redistribution of CD8+ T cell subsets in metastatic renal cell carcinoma patients treated with anti-PD-1 therapy.
- Author
-
De Biasi S, Guida A, Lo Tartaro D, Fanelli M, Depenni R, Dominici M, Finak G, Porta C, Paolini A, Borella R, Bertoldi C, Cossarizza A, Sabbatini R, and Gibellini L
- Subjects
- CD8-Positive T-Lymphocytes, Humans, T-Lymphocyte Subsets, Carcinoma, Renal Cell drug therapy, Carcinoma, Renal Cell pathology, Kidney Neoplasms drug therapy, Kidney Neoplasms pathology
- Abstract
Renal-cell carcinoma (RCC) is responsible for the majority of tumors arising from the kidney parenchyma. Although a progressive improvement in median overall survival has been observed after the introduction of anti-PD-1 therapy, many patients do not benefit from this treatment. Therefore, we have investigated T cell dynamics to find immune modification induced by anti-PD-1 therapy. Here, we show that, after therapy, RCC patients (5 responders and 14 nonresponders) are characterized by a redistribution of different subsets across the memory T cell compartment., (© 2022 The Authors. Cytometry Part A published by Wiley Periodicals LLC on behalf of International Society for Advancement of Cytometry.)
- Published
- 2022
- Full Text
- View/download PDF